Use of an animal model of disease for toxicology enables identification of a juvenile no observed adverse effect level for cyclocreatine in creatine transporter deficiency.

Do, Minh-Ha Thi; Cavagnaro, Joy; Butt, Mark; Terse, Pramod S; McKew, John C

Do, Minh-Ha Thi; Cavagnaro, Joy; Butt, Mark; Terse, Pramod S; McKew, John C.

Affiliation

Do MT; Lumos Pharma, 4200 Marathon Blvd Suite 200, Austin, TX, 78756, USA.
Cavagnaro J; Access Bio, P.O. Box 240, Boyce, VA, 22620, USA.
Butt M; Tox Path Specialists, 8420 Gas House Pike Suite G, Frederick, MD, 21701, USA.
Terse PS; National Center for Advancing Translational Sciences, National Institute of Health, 9800 Medical Center Drive, Rockville, MD, 20850, USA.
McKew JC; Lumos Pharma, 4200 Marathon Blvd Suite 200, Austin, TX, 78756, USA. Electronic address: jmckew@lumos-pharma.com.

Regul Toxicol Pharmacol ; 123: 104939, 2021 Jul.

Article in En | MEDLINE | ID: mdl-33961952

Subject(s)

Antineoplastic Agents/toxicity; Creatinine/analogs & derivatives; Disease Models, Animal; Animals; Brain; Brain Diseases, Metabolic, Inborn; Creatine/deficiency; Creatinine/toxicity; Humans; Membrane Transport Proteins; Mental Retardation, X-Linked; Mice; No-Observed-Adverse-Effect Level; Plasma Membrane Neurotransmitter Transport Proteins/deficiency; Seizures; Tissue Distribution

Key words

Animal models of disease; Creatine analog; Creatine transporter deficiency; Cyclocreatine; Non-conventional toxicology; Preclinical toxicity; SLC6A8

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Creatinine / Disease Models, Animal / Antineoplastic Agents Type of study: Diagnostic_studies / Prognostic_studies Limits: Animals / Humans Language: En Journal: Regul Toxicol Pharmacol Year: 2021 Type: Article Affiliation country: United States

Fulltext

XML

PubMed Links

Search on Google